Golden Biotechnology Corporation (4132.TWO)
TWD 15.0
(-0.33%)
TWD 15.0
(-0.33%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -271.31 Million | -245.9 Million | -197.96 Million | -259.59 Million | -222.98 Million |
| Net Income | -361.34 Million | -271.76 Million | -441.53 Million | -388.82 Million | -285.12 Million |
| Depreciation & Amortization | 51.02 Million | 51.2 Million | 51.18 Million | 56.9 Million | 64.11 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | 21.7 Million | - | - |
| Change in working capital | 39.24 Million | -25.99 Million | 156.85 Million | 42.41 Million | -13.59 Million |
| Other non-cash items | -2.08 Million | -250 Thousand | 11.1 Million | 4.35 Million | 11.62 Million |
| Investing Cash Flow | -18.63 Million | 63.47 Million | -114.02 Million | -14.13 Million | 28.04 Million |
| Investments in PPE | -7.97 Million | -18.03 Million | -10.15 Million | -10.66 Million | -10.89 Million |
| Acquisitions | 1.52 Million | - | - | - | - |
| Investment purchases | - | 83.04 Million | -83.04 Million | - | - |
| Sales/Maturities of investments | - | - | - | - | 50 Million |
| Other Investing Activities | -12.19 Million | -2.43 Million | -20.83 Million | -3.47 Million | 38.94 Million |
| Financing Cash Flow | -21.79 Million | -26.31 Million | 618.27 Million | 564.54 Million | 85.15 Million |
| Debt repayment | -6.6 Million | -13.61 Million | -56.33 Million | -46.02 Million | -33.53 Million |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | 580 Million | 539.2 Million | 68.28 Million |
| Other Financing Activities | -15.19 Million | -2 Million | 652 Million | 589.2 Million | 50.4 Million |
| Accounts receivables | 1.01 Million | -567 Thousand | -774 Thousand | 2.16 Million | 1.91 Million |
| Accounts payables | 706 Thousand | - | - | - | - |
| Inventory | -498 Thousand | 70.52 Million | 71.74 Million | 32.3 Million | -12.81 Million |
| Other working capital | 36.02 Million | 17.4 Million | -27.47 Million | 8.23 Million | -2.69 Million |
| Cash at beginning of period | 523.48 Million | 731.56 Million | 427.92 Million | 137.8 Million | 247.88 Million |
| Cash at end of period | 210.88 Million | 523.48 Million | 731.56 Million | 427.92 Million | 137.8 Million |
| Capital Expenditure | -7.97 Million | -18.03 Million | -10.15 Million | -10.66 Million | -10.89 Million |
| Effect of forex changes on cash | -848 Thousand | 667 Thousand | -2.64 Million | -689 Thousand | -297 Thousand |
| Net cash flow / Change in cash | -312.59 Million | -208.08 Million | 303.63 Million | 290.12 Million | -110.08 Million |
| Free Cash Flow | -279.28 Million | -263.94 Million | -208.11 Million | -270.26 Million | -233.87 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -80.39 Million | -80.39 Million | -109.25 Million | -361.34 Million | -109.25 Million | -71.56 Million |
| Depreciation & Amortization | 11.81 Million | 11.81 Million | 11.86 Million | 51.02 Million | 11.86 Million | 12.76 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 908.5 Thousand | 908.5 Thousand | 38.14 Million | 39.24 Million | 38.14 Million | -19.87 Million |
| Other non-cash items | -152 Thousand | -152 Thousand | 1.53 Million | -2.08 Million | 1.53 Million | 729.5 Thousand |
| Investing Cash Flow | -5.47 Million | -5.47 Million | -4.8 Million | -18.63 Million | -4.8 Million | -4.51 Million |
| Investments in PPE | -30.5 Thousand | -30.5 Thousand | -382.5 Thousand | -7.97 Million | -382.5 Thousand | -2.06 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | -5.44 Million | -5.44 Million | -4.42 Million | -12.19 Million | -4.42 Million | -2.45 Million |
| Financing Cash Flow | 12.82 Million | 12.82 Million | -5.9 Million | -21.79 Million | -5.9 Million | -4.99 Million |
| Debt repayment | -33.18 Million | - | - | -6.6 Million | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | 12.82 Million | 12.82 Million | -5.9 Million | - | -5.9 Million | -4.99 Million |
| Accounts receivables | 198 Thousand | 198 Thousand | 220 Thousand | 1.01 Million | 220 Thousand | 287.5 Thousand |
| Accounts payables | -149 Thousand | - | - | - | - | - |
| Inventory | 2.87 Million | 2.87 Million | 5.93 Million | -498 Thousand | 5.93 Million | -6.18 Million |
| Other working capital | -2.15 Million | -2.15 Million | 31.99 Million | 36.02 Million | 31.99 Million | -13.97 Million |
| Cash at beginning of period | 210.88 Million | - | - | 523.48 Million | - | - |
| Cash at end of period | -60.76 Million | -60.76 Million | -68.36 Million | 210.88 Million | -68.36 Million | -87.93 Million |
| Capital Expenditure | -30.5 Thousand | -30.5 Thousand | -382.5 Thousand | -7.97 Million | -382.5 Thousand | -2.06 Million |
| Effect of forex changes on cash | -290.5 Thousand | -290.5 Thousand | 60.5 Thousand | -848 Thousand | 60.5 Thousand | -484.5 Thousand |
| Net cash flow / Change in cash | -271.65 Million | -60.76 Million | -68.36 Million | -312.59 Million | -68.36 Million | -87.93 Million |
| Free Cash Flow | -67.86 Million | -67.86 Million | -58.09 Million | -279.28 Million | -58.09 Million | -80 Million |
ATLPF
100120
IPIC
PINF
NYMXF
003030